Feed SLXNW
SL

Silexion Therapeutics Ltd.

SLXNW · NASDAQ

$0.01 -62.50% (-$0.02)
1M -40.00%
Market Cap $6.73K
P/E Ratio -
Div. Yield -
ROE 276.59%

Bulios Fair Price

$0.01

16.7% downside

Current Price

$0.012

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SLXNW is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
2/9
Valuation
100 /100
Cheap
P/B 0.15x
PEG N/A
P/E N/A
Growth
-
N/A
FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
40 /100
Average
ROA 161.47%
ROIC 628.40%
Asset turnover 0.00x
Debt
8 /100
High
Int. coverage -2,346.83x
Debt/Equity 32.05x
Current ratio 0.94x
Stability
19 /100
Unstable
Profitable years 0
Beta -0.27x
EPS volatility 7,313.59%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SLXNW
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Ilan Hadar

Employees

14

Headquarters

Jerusalem

Upcoming events

18 NOV

Earnings

Upcoming earnings report

70d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.